Effect of soy isoflavones on circulating C-reactive protein in postmenopausal women: Meta-analysis of randomized controlled trials

Menopause

Volumn 18, Issue 11, 2011, Pages 1256-1262

  Dong, Jia Yi ^a   Wang, Peiyu ^b   He, Ka ^c   Qin, Li Qiang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c University of North Carolina   (United States)

Author keywords

C reactive protein; Isoflavones; Meta analysis; Postmenopausal women

Indexed keywords

C REACTIVE PROTEIN; ISOFLAVONE; PLANT EXTRACT; SOY ISOFLAVONE; SOYBEAN PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BODY MASS; COCHRANE LIBRARY; HUMAN; MEDLINE; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; POSTMENOPAUSE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SOYBEAN; SOYBEAN MILK; TREATMENT DURATION; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; DIETARY SUPPLEMENTS; FEMALE; HUMANS; ISOFLAVONES; POSTMENOPAUSE; SOY FOODS;

EID: 80255133220     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0b013e31821bfa24     Document Type: Article

References (48)

1. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and metaanalyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009;151:483-495.
2. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-140.
3. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statisticsV2010 update: a report from the American Heart Association. Circulation 2010;121:e46-e215.
4. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207.
5. Zhang X, Shu XO, Gao YT, et al. Soy food consumption is associated with lower risk of coronary heart disease in Chinese women. J Nutr 2003; 133:2874-2878. (Pubitemid 37099774)
6. Kokubo Y, Iso H, Ishihara J, Okada K, Inoue M, Tsugane S. Association of dietary intake of soy, beans, and isoflavones with risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health Center-based (JPHC) study cohort I. Circulation 2007;116:2553-2562. (Pubitemid 350179220)
7. Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2008;88:38-50. (Pubitemid 351988681)
8. Taku K, Umegaki K, Sato Y, Taki Y, Endoh K, Watanabe S. Soy isoflavones lower serum total and LDL cholesterol in humans: a metaanalysis of 11 randomized controlled trials. Am J Clin Nutr 2007;85: 1148-1156. (Pubitemid 46557934)
9. Zhuo XG, Melby MK, Watanabe S. Soy isoflavone intake lowers serum LDL cholesterol: a meta-analysis of 8 randomized controlled trials in humans. J Nutr 2004;134:2395-2400. (Pubitemid 39201614)
10. Verdrengh M, Jonsson IM, Holmdahl R, Tarkowski A. Genistein as an anti-inflammatory agent. Inflamm Res 2003;52:341-346. (Pubitemid 36995159)
11. Rimbach G, Weinberg PD, de Pascual-Teresa S, et al. Sulfation of genistein alters its antioxidant properties and its effect on platelet aggregation and monocyte and endothelial function. Biochim Biophys Acta 2004;1670: 229-237. (Pubitemid 38229773)
12. Register TC, Cann JA, Kaplan JR, et al. Effects of soy isoflavones and conjugated equine estrogens on inflammatory markers in atherosclerotic, ovariectomized monkeys. J Clin Endocrinol Metab 2005;90:1734-1740. (Pubitemid 40464046)
13. Chun OK, Chung SJ, Claycombe KJ, Song WO. Serum C-reactive protein concentrations are inversely associated with dietary flavonoid intake in U.S. adults. J Nutr 2008;138:753-760. (Pubitemid 351469420)
14. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-269, W264.
15. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006;8:538-554. (Pubitemid 44184248)
16. Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003;139:670-682. (Pubitemid 38124539)
17. Kinlay S. Low-density lipoprotein-dependent and-independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007;49:2003-2009. (Pubitemid 46734641)
18. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17:1-12. (Pubitemid 26120810)
19. Follmann D, Elliott P, Suh I, Cutler J. Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 1992;45: 769-773.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560. (Pubitemid 37088507)
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-634. (Pubitemid 27387172)
22. Teede HJ, Dalais FS, McGrath BP. Dietary soy containing phytoestrogens does not have detectable estrogenic effects on hepatic protein synthesis in postmenopausal women. Am J Clin Nutr 2004;79:396-401. (Pubitemid 41115582)
23. Colacurci N, Chiantera A, Fornaro F, et al. Effects of soy isoflavones on endothelial function in healthy postmenopausal women. Menopause 2005; 12:299-307. (Pubitemid 40664212)
24. D'Anna R, Baviera G, Corrado F, Cancellieri F, Crisafulli A, Squadrito F. The effect of the phytoestrogen genistein and hormone replacement therapy on homocysteine and C-reactive protein level in postmenopausal women. Acta Obstet Gynecol Scand 2005;84:474-477. (Pubitemid 40663448)
25. Hall WL, Vafeiadou K, Hallund J, et al. Soy-isoflavone-enriched foods and inflammatory biomarkers of cardiovascular disease risk in postmenopausal women: interactions with genotype and equol production. Am J Clin Nutr 2005;82:1260-1268; quiz 1365-1366. (Pubitemid 43779725)
26. Yildiz MF, Kumru S, Godekmerdan A, Kutlu S. Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. Int J Gynaecol Obstet 2005;90: 128-133. (Pubitemid 40981950)
27. Hanson LN, Engelman HM, Alekel DL, Schalinske KL, Kohut ML, Reddy MB. Effects of soy isoflavones and phytate on homocysteine, C-reactive protein, and iron status in postmenopausal women. Am J Clin Nutr 2006;84:774-780. (Pubitemid 44715659)
28. Lukaczer D, Liska DJ, Lerman RH, et al. Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. Nutrition 2006;22:104-113. (Pubitemid 43188799)
29. Ryan-Borchers TA, Park JS, Chew BP, McGuire MK, Fournier LR, Beerman KA. Soy isoflavones modulate immune function in healthy postmenopausal women. Am J Clin Nutr 2006;83:1118-1125.
30. Aubertin-Leheudre M, Lord C, Khalil A, Dionne IJ. Effect of 6 months of exercise and isoflavone supplementation on clinical cardiovascular risk factors in obese postmenopausal women: a randomized, double-blind study. Menopause 2007;14:624-629. (Pubitemid 47051954)
31. Azadbakht L, Kimiagar M, Mehrabi Y, Esmaillzadeh A, Hu FB, Willett WC. Soy consumption, markers of inflammation, and endothelial function: a cross-over study in postmenopausal women with the metabolic syndrome. Diabetes Care 2007;30:967-973. (Pubitemid 46556594)
32. Gonzalez S, Jayagopal V, Kilpatrick ES, Chapman T, Atkin SL. Effects of isoflavone dietary supplementation on cardiovascular risk factors in type 2 diabetes. Diabetes Care 2007;30:1871-1873. (Pubitemid 47036369)
33. Greany KA, Nettleton JA, Wangen KE, Thomas W, Kurzer MS. Consumption of isoflavone-rich soy protein does not alter homocysteine or markers of inflammation in postmenopausal women. Eur J Clin Nutr 2008;62:1419-1425. (Pubitemid 352807336)
34. Nasca MM, Zhou JR, Welty FK. Effect of soy nuts on adhesion molecules and markers of inflammation in hypertensive and normotensive postmenopausal women. Am J Cardiol 2008;102:84-86.
35. Verhoeven MO, Teerlink T, Kenemans P, Zuijdgeest-van Leeuwen SD, van der Mooren MJ. Effects of a supplement containing isoflavones and Actaea racemosa L. on asymmetric dimethylarginine, lipids, and C-reactive protein in menopausal women. Fertil Steril 2007;87:849-857. (Pubitemid 46550416)
36. Nikander E, Metsa-Heikkila M, Tiitinen A, Ylikorkala O. Evidence of a lack of effect of a phytoestrogen regimen on the levels of C-reactive protein, E-selectin, and nitrate in postmenopausal women. J Clin Endocrinol Metab 2003;88:5180-5185. (Pubitemid 37455409)
37. Tormala R, Appt S, Clarkson TB, et al. Impact of soy supplementation on sex steroids and vascular inflammation markers in postmenopausal women using tibolone: role of equol production capability. Climacteric 2008;11:409-415.
38. Christie DR, Grant J, Darnell BE, Chapman VR, Gastaldelli A, Sites CK. Metabolic effects of soy supplementation in postmenopausal Caucasian and African American women: a randomized, placebo-controlled trial. Am J Obstet Gynecol 2010;203:153e1-9.
39. Hardy RJ, Thompson SG. Detecting and describing heterogeneity in meta-analysis. Stat Med 1998;17:841-856. (Pubitemid 28185164)
40. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.2. London, England: The Cochrane Collaboration, 2009.
41. Chan YH, Lau KK, Yiu KH, et al. Reduction of C-reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. Eur Heart J 2008;29:2800-2807.
42. Azadbakht L, Atabak S, Esmaillzadeh A. Soy protein intake, cardiorenal indices, and C-reactive protein in type 2 diabetes with nephropathy: a longitudinal randomized clinical trial. Diabetes Care 2008;31:648-654.
43. Setchell KD, Clerici C. Equol: pharmacokinetics and biological actions. J Nutr 2010;140:1363S-1368S.
44. Setchell KD, Clerici C. Equol: history, chemistry, and formation. J Nutr 2010;140:1355S-1362S.
45. Barnes PJ, Karin M. Nuclear factor-JB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-1071. (Pubitemid 27163860)
46. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Overexpressed nuclear factor-JB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPA and signal transducer and activator of transcription-3. Immunology 2003;108:539-547. (Pubitemid 36469692)
47. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-JB activation in prostate cancer cells. Nutr Cancer 1999;35:167-174. (Pubitemid 30115128)
48. Kim JW, Jin YC, Kim YM, et al. Daidzein administration in vivo reduces myocardial injury in a rat ischemia/reperfusion model by inhibiting NF-JB activation. Life Sci 2009;84:227-234.